Choon Kwan Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Choon Kwan Kim has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Won Sup Oh
Gangwon State Center for Infectious Diseases, Chuncheon, Korea
5 shared publications - Kyong Ran Peck
Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
4 shared publications - Shin-Woo Kim
Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea
4 shared publications Hyuck Lee
Dong-A University Hospital, Busan
3 shared publicationsSook-In Jung
Chonnam National University Hospital, Gwangju, South Korea
3 shared publications- Yeon-Sook Kim
Division of Infectious Diseases, Department of Internal Medicine, Chungnam National University School of Medicine
3 shared publications
Latest Publications
- Open Access
- 10 November 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (45) , e35987
Clinical outcomes of mild to moderate coronavirus disease 2019 patients treated with Regdanvimab in delta-variant outbreak: Retrospective cohort study
Regdanvimab is a novel neutralizing antibody agent used for the treatment of coronavirus disease 2019 (COVID-19). However, the effectiveness of regdanvimab in delta-variant patients has rarely been investigated. We examined the clinical outcomes and adverse events in COVID 19 patients treated with regdanvimab in the delta-variant era. Data were collected from laboratory-confirmed COVID-19 hospitalized patients who received regdanvimab in 2021 and categorized into pre-delta and delta variant groups. The primary outcome was the need for oxygen therapy. Rescue therapy, clinical improvement, and adverse events were analyzed. Among 101 patients treated with regdanvimab, 31 (30.7%) were delta patients and 49 (48.5) were pre-delta patients. 64.4% were male, the mean age was 60.3 years, and 70 patients (69%) had at least one underlying disease. The median interval from symptom onset to injection was 4 days. Twenty-three patients (23%) needed oxygen therapy, including 9 (29%) in the delta and 8 (16.3%) in the pre-delta group. (P = .176) The risk of early oxygen supplement was higher in the delta group (adjusted hazard ratio (aHR), 6.75; 95% confidence interval(CI), 1.53–29.8). The in-hospital survival rate was 100%, and no patients were admitted to the intensive care unit. Adverse events occurred in 43% of patients:13 (42%) delta patients and 23 (47%) pre-delta patients had any adverse events (P = .661). Patients treated with regdanvimab 4 days after symptom onset showed a favorable prognosis (aHR, 0.26; 95% CI, 0.26–0.91). We found that the high-risk mild to moderate COVID-19 patients treated with regdanvimab showed similar disease progression in delta-variant patients and pre-delta variants; however, we need to be more closely observed delta-variant patients than those in the pre-delta group despite regdanvimab treatment due to rapid disease aggravation.
- 10 November 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (45) , e35987
Open AccessClinical outcomes of mild to moderate coronavirus disease 2019 patients treated with Regdanvimab in delta-variant outbreak: Retrospective cohort study
Regdanvimab is a novel neutralizing antibody agent used for the treatment of coronavirus disease 2019 (COVID-19). However, the effectiveness of regdanvimab in delta-variant patients has rarely been investigated. We examined the clinical outcomes and adverse events in COVID 19 patients treated with regdanvimab in the delta-variant era. Data were collected from laboratory-confirmed COVID-19 hospitalized patients who received regdanvimab in 2021 and categorized into pre-delta and delta variant groups. The primary outcome was the need for oxygen therapy. Rescue therapy, clinical improvement, and adverse events were analyzed. Among 101 patients treated with regdanvimab, 31 (30.7%) were delta patients and 49 (48.5) were pre-delta patients. 64.4% were male, the mean age was 60.3 years, and 70 patients (69%) had at least one underlying disease. The median interval from symptom onset to injection was 4 days. Twenty-three patients (23%) needed oxygen therapy, including 9 (29%) in the delta and 8 (16.3%) in the pre-delta group. (P = .176) The risk of early oxygen supplement was higher in the delta group (adjusted hazard ratio (aHR), 6.75; 95% confidence interval(CI), 1.53–29.8). The in-hospital survival rate was 100%, and no patients were admitted to the intensive care unit. Adverse events occurred in 43% of patients:13 (42%) delta patients and 23 (47%) pre-delta patients had any adverse events (P = .661). Patients treated with regdanvimab 4 days after symptom onset showed a favorable prognosis (aHR, 0.26; 95% CI, 0.26–0.91). We found that the high-risk mild to moderate COVID-19 patients treated with regdanvimab showed similar disease progression in delta-variant patients and pre-delta variants; however, we need to be more closely observed delta-variant patients than those in the pre-delta group despite regdanvimab treatment due to rapid disease aggravation.
- Open Access
- 1 January 2023
- Published by XMLink in Infection & Chemotherapy
- Vol. 55 (1) , 25-36
Magnitude and Duration of Serum Neutralizing Antibody Titers Induced by a Third mRNA COVID-19 Vaccination against Omicron BA.1 in Older Individuals
Park JS, et al. Infect Chemother. 2023 Nov;55:e47. https://doi.org/10.3947/ic.2023.0057
- 1 January 2023
- Published by XMLink in Infection & Chemotherapy
- Vol. 55 (1) , 25-36
Open AccessMagnitude and Duration of Serum Neutralizing Antibody Titers Induced by a Third mRNA COVID-19 Vaccination against Omicron BA.1 in Older Individuals
Park JS, et al. Infect Chemother. 2023 Nov;55:e47. https://doi.org/10.3947/ic.2023.0057
- Open Access
Superantigen-Producing Staphylococcus aureus Elicits Systemic Immune Activation in a Murine Wound Colonization Model
Staphylococcus aureus, the most common cause of wound infection, produces several exotoxins, including superantigens (SAgs). SAgs are the potent activators of the immune system. Given this unique property, we hypothesized that SAgs produced by S. aureus in wounds would have local, as well as systemic immunologic effects. We tested our hypothesis using a novel staphylococcal skin wound infection model in transgenic mice expressing HLA-DR3. Skin wounds were left uninfected or colonized with S. aureus strains producing SAgs or an isogenic strain not producing any SAg. Animals with wounds challenged with SAg-producing S. aureus had increased morbidity and lower serum IL-17 levels compared to those challenged with the SAg non-producing S. aureus (p = 0.027 and p = 0.032, respectively). At Day 8 following microbial challenge, compared to mice with uninfected wounds, the proportion of Vβ8+CD4+ T cells was increased, while the proportion of Vβ8+CD8+ T cells was decreased only in the spleens of mice challenged with SAg-producing S. aureus (p < 0.001). No such changes were measured in mice challenged with SAg non-producing S. aureus. Lungs, livers and kidneys from mice challenged with SAg-producing, but not SAg non-producing, S. aureus showed inflammatory changes. Overall, SAg-mediated systemic immune activation in wounds harboring S. aureus may have clinical implications.
Open AccessSuperantigen-Producing Staphylococcus aureus Elicits Systemic Immune Activation in a Murine Wound Colonization Model
Staphylococcus aureus, the most common cause of wound infection, produces several exotoxins, including superantigens (SAgs). SAgs are the potent activators of the immune system. Given this unique property, we hypothesized that SAgs produced by S. aureus in wounds would have local, as well as systemic immunologic effects. We tested our hypothesis using a novel staphylococcal skin wound infection model in transgenic mice expressing HLA-DR3. Skin wounds were left uninfected or colonized with S. aureus strains producing SAgs or an isogenic strain not producing any SAg. Animals with wounds challenged with SAg-producing S. aureus had increased morbidity and lower serum IL-17 levels compared to those challenged with the SAg non-producing S. aureus (p = 0.027 and p = 0.032, respectively). At Day 8 following microbial challenge, compared to mice with uninfected wounds, the proportion of Vβ8+CD4+ T cells was increased, while the proportion of Vβ8+CD8+ T cells was decreased only in the spleens of mice challenged with SAg-producing S. aureus (p < 0.001). No such changes were measured in mice challenged with SAg non-producing S. aureus. Lungs, livers and kidneys from mice challenged with SAg-producing, but not SAg non-producing, S. aureus showed inflammatory changes. Overall, SAg-mediated systemic immune activation in wounds harboring S. aureus may have clinical implications.
- 1 March 2015
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 81 (3) , 201-207
Superantigens in Staphylococcus aureus isolated from prosthetic joint infection
- 1 March 2015
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 81 (3) , 201-207
Superantigens in Staphylococcus aureus isolated from prosthetic joint infection
- Open Access
- 1 January 2014
- Published by Korean Association of Internal Medicine in The Korean Journal of Medicine
- Vol. 87 (2) , 245-250
A Case of Adult Onset Still's Disease with Severe Pneumonitis Treated with Anakinra
Cho SH, et al. Korean J Med. 2014 Aug;87(2):245-250. http://dx.doi.org/10.3904/kjm.2014.87.2.245
- 1 January 2014
- Published by Korean Association of Internal Medicine in The Korean Journal of Medicine
- Vol. 87 (2) , 245-250
Open AccessA Case of Adult Onset Still's Disease with Severe Pneumonitis Treated with Anakinra
Cho SH, et al. Korean J Med. 2014 Aug;87(2):245-250. http://dx.doi.org/10.3904/kjm.2014.87.2.245
- Open Access
- 1 January 2013
- Published by Korean Association of Internal Medicine in The Korean Journal of Medicine
- Vol. 84 (4) , 613
A Case of Systemic Lupus Erythematosus-Associated Hemophagocytic Lymphohistiocytosis Treated Successfully with an Etoposide Infusion
- 1 January 2013
- Published by Korean Association of Internal Medicine in The Korean Journal of Medicine
- Vol. 84 (4) , 613
Open AccessA Case of Systemic Lupus Erythematosus-Associated Hemophagocytic Lymphohistiocytosis Treated Successfully with an Etoposide Infusion
- Open Access
- 1 January 2012
- Published by Korean Society of Coloproctology in Journal of the Korean Society of Coloproctology
- Vol. 28 (6) , 325-329
Necrotizing Fasciitis of the Thigh Secondary to Radiation Colitis in a Rectal Cancer Patient
Park SH, et al. J Korean Soc Coloproctol. 2012 Dec;28(6):325-329. http://dx.doi.org/10.3393/jksc.2012.28.6.325
- 1 January 2012
- Published by Korean Society of Coloproctology in Journal of the Korean Society of Coloproctology
- Vol. 28 (6) , 325-329
Open AccessNecrotizing Fasciitis of the Thigh Secondary to Radiation Colitis in a Rectal Cancer Patient
Park SH, et al. J Korean Soc Coloproctol. 2012 Dec;28(6):325-329. http://dx.doi.org/10.3393/jksc.2012.28.6.325
- Open Access
- 1 January 2011
- Published by Korean Society of Infectious Diseases and Korean Society for Chemotherapy in Infection & Chemotherapy
- Vol. 43 (3) , 262-265
Treatment of Neurosyphilis with Ceftriaxone in a Patient Infected with Human Immunodeficiency Virus
Si WK, et al. Infect Chemother. 2011 Jun;43(3):262-265. http://dx.doi.org/10.3947/ic.2011.43.3.262
- 1 January 2011
- Published by Korean Society of Infectious Diseases and Korean Society for Chemotherapy in Infection & Chemotherapy
- Vol. 43 (3) , 262-265
Open AccessTreatment of Neurosyphilis with Ceftriaxone in a Patient Infected with Human Immunodeficiency Virus
Si WK, et al. Infect Chemother. 2011 Jun;43(3):262-265. http://dx.doi.org/10.3947/ic.2011.43.3.262
- Open Access
- 1 December 2005
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (12) , 5176-5178
High Rate of Resistance to Quinupristin-Dalfopristin in Enterococcus faecium Clinical Isolates from Korea
We tested the in vitro susceptibilities of 603 enterococcal isolates from eight tertiary-care hospitals in Korea. The quinupristin-dalfopristin resistance rate in Enterococcus faecium was very high (25 isolates, 10.0%). It was suggested that both clonal spread and the sporadic emergence of quinupristin-dalfopristin-resistant isolates may explain the high prevalence of quinupristin-dalfopristin resistance in Korea.
- 1 December 2005
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (12) , 5176-5178
Open AccessHigh Rate of Resistance to Quinupristin-Dalfopristin in Enterococcus faecium Clinical Isolates from Korea
We tested the in vitro susceptibilities of 603 enterococcal isolates from eight tertiary-care hospitals in Korea. The quinupristin-dalfopristin resistance rate in Enterococcus faecium was very high (25 isolates, 10.0%). It was suggested that both clonal spread and the sporadic emergence of quinupristin-dalfopristin-resistant isolates may explain the high prevalence of quinupristin-dalfopristin resistance in Korea.